Practical thinking on collateral strategy, the review process, and what makes pharmaceutical promotional materials work in the field.
A brand team ran five pages through Collateral Advisor before MLR. On one page it clarified an open question; on another it matched their own medical experts’ judgement. Now a paying subscriber.
Read the case study →What UCPMP 2024 changed for the pharma brand manager. The brand reminder limit, free sample caps, gifts to doctors, CME, and how the code is actually enforced.
How a UCPMP complaint works, the penalties the ethics committee can impose, the appeal route, and the CEO self-declaration. A practitioner guide for pharma brand teams.
UCPMP is not the only rulebook. The DMRA, the Drugs and Cosmetics Act schedules and the ASCI code decide what a claim on a visual aid can say. A practitioner guide.
Prescription drug advertising to the public is restricted in India. What Schedules H, H1 and X mean for pharma collateral, and the line brand teams cross by accident.
MLR approval delay is mostly rework, and rework is set before submission. How a structured pre-MLR read by the brand team cuts revision rounds in Indian pharma.
Before design, a pharma visual aid and LBL must carry what UCPMP promotional rules expect. The quiet, non-creative reasons collaterals bounce, explained for brand teams.
When a pharma visual aid goes through three or four revision rounds between the brand team and the designer, the easy assumption is that the designer is not getting the creative right. Rarely the real story.
Most brand teams focus on getting a visual aid designed, approved, and into the field as fast as possible. But speed without scrutiny creates a different kind of problem. Collaterals go through multiple revision rounds.
When we started exploring what it would look like for brand teams to review their own collaterals before submitting for medical and regulatory approval, we had a clear assumption about where the value would come from.
When a pharma collateral gets stuck in the review cycle, most people assume the issue is medical accuracy. A claim the data cannot support. An MOA description that oversimplifies the mechanism.
Every pharma collateral is shaped by two forces that pull in opposite directions. The marketing team wants the collateral to stand out. The medical team wants the collateral to be safe.
Every pharma collateral goes through a review process designed to answer two questions. Is the content medically accurate? Is it regulatory compliant? Both are essential. But there is a third question that almost no review process asks.
A busy specialist in a metro city sees MR after MR through the day. In some specialties, the number is overwhelming. Each MR carries a visual aid. Each one gets somewhere between 60 and 120 seconds.